创始人
王喆 博士
创始人、董事长
王喆博士师从诺贝尔化学奖得主 E.J. Corey教授，从事药物开发研究工作20余年，有领导从立项到药物上市的完整产业链经验，在抗感染、抗病毒及抗癌新药研发领域有极深的造诣与卓越成就。
Founder
Dr. Zhe WANG
Founder, chairman
Dr. Zhe WANG studied under Prof. E.J. Corey, a Nobel laureate in chemistry.
With more than 20 years engaged in drug research and development, Dr. Zhe WANG has full experience of leading drug development from project initiation to drug launch. He has profound attainments and outstanding achievements in the field of new drug of anti-infection, anti-virus and anti-cancer.
研发体系
长森药业聚焦自身免疫疾病、肿瘤免疫治疗、抗病毒等领域的创新药研发与产业化，管线产品临床评估指标均达到国际领先水平，有望成为相关领域的重大突破（FIC，first in class）。
长森药业专注具有自主知识产权及国际领先水平的创新药物的开发和医学转化，通过合作开发、Licensing Out等形式，积极参与国际竞争，解决尚未满足的临床需求。
R&D
Longwood Biopharma is focusing on the development and industrialization of innovative drugs in the fields of autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).
Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR, and actively participates in international competition through co-development and licensing-out to address unmet clinical needs.
新闻资讯
【长森快讯】新一代口服JAK1选择性抑制剂LW402特应性皮炎临床II期研究完成全部受试者入组
近日，长森药业自主研发的新一代口服JAK1选择性抑制剂LW402在一项关于特应性皮炎（AD）的临床II研究已完成全部受试者入组...
【长森快讯】新一代口服JAK1选择性抑制剂LW402类风湿性关节炎临床II期研究结果展现惊人疗效
近日，长森药业发布了自主研发的新一代口服JAK1选择性抑制剂LW402在一项关于类风湿性关节炎（RA）的临床II期研究成果。
News
【LWBP NEWS】Next-Generation Oral JAK1-Selective Inhibitor LW402 Clinical Phase II Study in Atopic Dermatitis Completes Enrollment of All Subjects
Recently, LW402, a new-generation oral JAK1-selective inhibitor independently developed by LWBP, has completed the enrollment of all subjects in a Clinical II study of atopic dermatitis (AD) ...
【LWBP NEWS】LW402, a new-generation oral JAK1 selective inhibitor, demonstrated amazing results in clinical phase II study for rheumatoid arthritis
Recently, LWBP released the results of a clinical phase II study of LW402, a self-developed next-generation oral JAK1 selective inhibitor, in rheumatoid arthritis (RA).
【LWBP NEWS】LW402, a next-generation oral JAK1-selective inhibitor independently developed by LWBP, was approved for clinical studies in vitiligo
Recently, LW402 was approved to conduct clinical studies in vitiligo. LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP.
